CD40 and neoplasm: Combination of a TLR4 agonist, agonistic anti-CD40, and anti-PD-1 improved the survival of mice bearing orthotopic tumors, and studies with additional tumor models suggest that this therapy promotes DC priming of naïve T cells and recruitment of antigen-specific T cells to the TME (145).